Ушбу ишга иқтибос қилган ишлар

2 та иш

Иш: First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

1. Nivolumab Combined with Chemotherapy in FGFR2 and PD-L1 Co- Expressing Metastatic Gastric Cancer: A Prospective Phase 2 NIVOFGFR2 Study

   Ilya Tsimafeyeu, Gunel Musayeva, Samira Mahmudova +4

   ПрепринтFibroblast Growth Factor ResearchResearch Square20240 иқтибос

   ABIABI:AkademIndex/openalex/2024.preprint.000205

2. A comprehensive review of immunotherapy in gastrointestinal tumors with a focus on the role of combination therapy with PARP inhibitors

   Saade Abdalkareem Jasim, Jitendra Gupta, Subasini Uthirapathy +7

   Шарҳ мақолаCancer Immunotherapy and BiomarkersNaunyn-Schmiedeberg s Archives of Pharmacology20250 иқтибос

   ABIABI:AkademIndex/openalex/2025.review-article.000180